FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383312880> ?p ?o ?g. }

• W4383312880 endingPage "880" @default.
• W4383312880 startingPage "868" @default.
• W4383312880 abstract "Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with chemoradiotherapy with curative intent but at the consequence of adverse effects on quality of life. We aimed to investigate if dysphagia-optimised intensity-modulated radiotherapy (DO-IMRT) reduced radiation dose to the dysphagia and aspiration related structures and improved swallowing function compared with standard IMRT.DARS was a parallel-group, phase 3, multicentre, randomised, controlled trial done in 22 radiotherapy centres in Ireland and the UK. Participants were aged 18 years and older, had T1-4, N0-3, M0 oropharyngeal or hypopharyngeal cancer, a WHO performance status of 0 or 1, and no pre-existing swallowing dysfunction. Participants were centrally randomly assigned (1:1) using a minimisation algorithm (balancing factors: centre, chemotherapy use, tumour type, American Joint Committee on Cancer tumour stage) to receive DO-IMRT or standard IMRT. Participants and speech language therapists were masked to treatment allocation. Radiotherapy was given in 30 fractions over 6 weeks. Dose was 65 Gy to primary and nodal tumour and 54 Gy to remaining pharyngeal subsite and nodal areas at risk of microscopic disease. For DO-IMRT, the volume of the superior and middle pharyngeal constrictor muscle or inferior pharyngeal constrictor muscle lying outside the high-dose target volume had a mandatory 50 Gy mean dose constraint. The primary endpoint was MD Anderson Dysphagia Inventory (MDADI) composite score 12 months after radiotherapy, analysed in the modified intention-to-treat population that included only patients who completed a 12-month assessment; safety was assessed in all randomly assigned patients who received at least one fraction of radiotherapy. The study is registered with the ISRCTN registry, ISRCTN25458988, and is complete.From June 24, 2016, to April 27, 2018, 118 patients were registered, 112 of whom were randomly assigned (56 to each treatment group). 22 (20%) participants were female and 90 (80%) were male; median age was 57 years (IQR 52-62). Median follow-up was 39·5 months (IQR 37·8-50·0). Patients in the DO-IMRT group had significantly higher MDADI composite scores at 12 months than patients in the standard IMRT group (mean score 77·7 [SD 16·1] vs 70·6 [17·3]; mean difference 7·2 [95% CI 0·4-13·9]; p=0·037). 25 serious adverse events (16 serious adverse events assessed as unrelated to study treatment [nine in the DO-IMRT group and seven in the standard IMRT group] and nine serious adverse reactions [two vs seven]) were reported in 23 patients. The most common grade 3-4 late adverse events were hearing impairment (nine [16%] of 55 in the DO-IMRT group vs seven [13%] of 55 in the standard IMRT group), dry mouth (three [5%] vs eight [15%]), and dysphagia (three [5%] vs eight [15%]). There were no treatment-related deaths.Our findings suggest that DO-IMRT improves patient-reported swallowing function compared with standard IMRT. DO-IMRT should be considered a new standard of care for patients receiving radiotherapy for pharyngeal cancers.Cancer Research UK." @default.
• W4383312880 created "2023-07-07" @default.
• W4383312880 creator A5006634339 @default.
• W4383312880 creator A5009387241 @default.
• W4383312880 creator A5009911414 @default.
• W4383312880 creator A5013814659 @default.
• W4383312880 creator A5015984938 @default.
• W4383312880 creator A5019514155 @default.
• W4383312880 creator A5020543753 @default.
• W4383312880 creator A5023166454 @default.
• W4383312880 creator A5026103937 @default.
• W4383312880 creator A5027361020 @default.
• W4383312880 creator A5032414954 @default.
• W4383312880 creator A5032482958 @default.
• W4383312880 creator A5032565927 @default.
• W4383312880 creator A5035901116 @default.
• W4383312880 creator A5039273695 @default.
• W4383312880 creator A5040317695 @default.
• W4383312880 creator A5041095922 @default.
• W4383312880 creator A5042688609 @default.
• W4383312880 creator A5044737178 @default.
• W4383312880 creator A5048782694 @default.
• W4383312880 creator A5053163084 @default.
• W4383312880 creator A5058708542 @default.
• W4383312880 creator A5059792318 @default.
• W4383312880 creator A5062380641 @default.
• W4383312880 creator A5063245199 @default.
• W4383312880 creator A5077877163 @default.
• W4383312880 creator A5080375325 @default.
• W4383312880 creator A5083381440 @default.
• W4383312880 creator A5085805875 @default.
• W4383312880 creator A5087346045 @default.
• W4383312880 date "2023-08-01" @default.
• W4383312880 modified "2023-10-12" @default.
• W4383312880 title "Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial" @default.
• W4383312880 cites W1981227718 @default.
• W4383312880 cites W1986565583 @default.
• W4383312880 cites W1987343012 @default.
• W4383312880 cites W1987714378 @default.
• W4383312880 cites W2010476323 @default.
• W4383312880 cites W2019607817 @default.
• W4383312880 cites W2034680644 @default.
• W4383312880 cites W2046104835 @default.
• W4383312880 cites W2057691621 @default.
• W4383312880 cites W2082101117 @default.
• W4383312880 cites W2084491906 @default.
• W4383312880 cites W2089297819 @default.
• W4383312880 cites W2091736377 @default.
• W4383312880 cites W2097877264 @default.
• W4383312880 cites W2110240958 @default.
• W4383312880 cites W2113220990 @default.
• W4383312880 cites W2117183012 @default.
• W4383312880 cites W2118772763 @default.
• W4383312880 cites W2127886998 @default.
• W4383312880 cites W2130068955 @default.
• W4383312880 cites W2136798509 @default.
• W4383312880 cites W2140110477 @default.
• W4383312880 cites W2148881900 @default.
• W4383312880 cites W2529631070 @default.
• W4383312880 cites W2911900398 @default.
• W4383312880 cites W3210616732 @default.
• W4383312880 cites W4240814623 @default.
• W4383312880 doi "https://doi.org/10.1016/s1470-2045(23)00265-6" @default.
• W4383312880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37423227" @default.
• W4383312880 hasPublicationYear "2023" @default.
• W4383312880 type Work @default.
• W4383312880 citedByCount "5" @default.
• W4383312880 countsByYear W43833128802023 @default.
• W4383312880 crossrefType "journal-article" @default.
• W4383312880 hasAuthorship W4383312880A5006634339 @default.
• W4383312880 hasAuthorship W4383312880A5009387241 @default.
• W4383312880 hasAuthorship W4383312880A5009911414 @default.
• W4383312880 hasAuthorship W4383312880A5013814659 @default.
• W4383312880 hasAuthorship W4383312880A5015984938 @default.
• W4383312880 hasAuthorship W4383312880A5019514155 @default.
• W4383312880 hasAuthorship W4383312880A5020543753 @default.
• W4383312880 hasAuthorship W4383312880A5023166454 @default.
• W4383312880 hasAuthorship W4383312880A5026103937 @default.
• W4383312880 hasAuthorship W4383312880A5027361020 @default.
• W4383312880 hasAuthorship W4383312880A5032414954 @default.
• W4383312880 hasAuthorship W4383312880A5032482958 @default.
• W4383312880 hasAuthorship W4383312880A5032565927 @default.
• W4383312880 hasAuthorship W4383312880A5035901116 @default.
• W4383312880 hasAuthorship W4383312880A5039273695 @default.
• W4383312880 hasAuthorship W4383312880A5040317695 @default.
• W4383312880 hasAuthorship W4383312880A5041095922 @default.
• W4383312880 hasAuthorship W4383312880A5042688609 @default.
• W4383312880 hasAuthorship W4383312880A5044737178 @default.
• W4383312880 hasAuthorship W4383312880A5048782694 @default.
• W4383312880 hasAuthorship W4383312880A5053163084 @default.
• W4383312880 hasAuthorship W4383312880A5058708542 @default.
• W4383312880 hasAuthorship W4383312880A5059792318 @default.
• W4383312880 hasAuthorship W4383312880A5062380641 @default.
• W4383312880 hasAuthorship W4383312880A5063245199 @default.
• W4383312880 hasAuthorship W4383312880A5077877163 @default.
• W4383312880 hasAuthorship W4383312880A5080375325 @default.
• W4383312880 hasAuthorship W4383312880A5083381440 @default.
• W4383312880 hasAuthorship W4383312880A5085805875 @default.

• next